Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data CNBX Pharmaceuticals Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2017
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.11
0.01
0.01
0.01
0.01
0
0.03
0.41
0.13
0
Gross profit
0.11
0.01
Research and development
0.18
0.25
1
1.54
1.68
1.77
1.18
0.43
0.19
0
Selling and marketing
0
0.29
0.42
0.29
0.06
0.02
General and administrative
0.21
1.33
2.39
1.48
1.31
0.83
1.8
0.91
0.52
0.27
Operating expenses
0.39
1.86
3.82
3.31
3.05
2.6
2.98
1.34
0.71
0.27
Operating income
-0.28
-1.85
-3.81
-3.3
-3.04
-2.6
-2.95
-0.93
-0.58
-0.27
Interest expense
0.01
0
0
0.04
Other non-operating income
-0.03
-0.07
0.03
4.44
-4.42
0.59
0.78
0.05
0.02
0.04
Net income
-0.31
-1.93
-3.78
1.13
-7.47
-3.19
-3.72
-3.71
-0.7
-0.31
EBITDA
-0.28
-1.85
-3.72
-3.11
-2.83
-2.38
-2.76
-0.77
-0.51
-0.27
EPS, basic
0.00
-0.02
-0.03
0.02
-0.10
-0.02
-3.59
-0.42
-0.02
0.00
EPS, diluted
0.00
-0.02
-0.03
0.02
-0.10
-0.02
-3.59
-0.42
-0.02
0.00
Shares, basic (weighted)
103
110
120
132
135
139
1.22
8.82
30.2
90.6
Shares, diluted (weighted)
103
110
120
132
135
139
1.22
8.82
30.2
90.6
Balance sheet
FY2016
FY2017
FY2017
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0.02
1.39
1.39
0.27
0.78
1.39
0.12
0.13
0.03
0.02
Short-term investments
0
3.26
0
Other current assets
0
0.15
0.23
0.28
0.15
0.2
0.08
0.09
0
0
Total current assets
0.02
3.52
1.62
4.31
0.93
1.59
0.2
0.22
0.03
0.02
Property, plant and equipment
0
0.12
0.97
1
0.86
0.64
0.44
0.27
0
0
Total assets
0.02
3.64
3.18
15.2
2.22
3.08
0.81
0.5
0.03
0.02
Accounts payable
0.27
0.39
0.32
0.22
0.23
0.18
0.46
0.34
0.04
0.05
Short-term debt
0
Total current liabilities
0.49
0.7
0.54
0.44
0.45
1.27
2.44
2.52
2.51
2.51
Total liabilities
0.49
6.58
0.54
0.44
0.45
1.27
-0.82
2.52
2.51
2.51
Paid-in capital
1.11
6.45
9.84
15.3
15.4
17.1
18
22.2
22.5
22.7
Retained earnings
-1.59
-3.52
-7.3
-6.16
-13.6
-16.8
-20.5
-24.3
-25
-25.3
Other comprehensive income
0
2.81
-2.77
-1.91
-2.57
0
0
0
Shareholders' equity
-0.47
-2.94
2.65
14.7
1.76
1.81
1.63
-2.02
-2.48
-2.5
Total equity
-0.47
-2.94
2.65
14.7
1.76
1.81
1.63
-2.02
-2.48
-2.5
Total liabilities and equity
0.02
3.64
3.18
15.2
2.22
3.08
0.81
0.5
0.03
0.02
Shares outstanding
107
120
122
134
135
149
1.24
22.6
31.1
554
Cash flow statement
FY2016
FY2017
FY2017
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-0.31
-1.93
0
4.36
-7.47
-3.19
-3.72
-3.71
-0.7
-0.31
Depreciation and amortization
0
0.01
0.09
0.19
0.22
0.22
0.2
0.16
0.07
0
Stock-based compensation
0.03
0.88
1.85
0.25
0.07
0
0.73
0.18
0.14
0
Change in payables
0.15
0.12
-0.07
-0.1
0.02
-0.05
0.28
0.49
0.04
0.1
Cash from operations
-0.12
-0.86
-1.97
-3.09
-2.77
-2.49
-1.68
-0.11
-0.24
-0.17
Cash from investing
0
-0.13
-1.44
-5.25
3.29
0.65
0.03
0.02
0.11
0
Debt repaid
0
-0
-0.02
0
Stock issued
0.09
4.41
1.55
7.29
0
Cash from financing
0.11
4.34
1.44
7.22
0
2.46
0.39
0.1
0.03
0.16
Exchange rate effect
0
-0
0
Net change in cash
-0.01
3.35
-1.97
-1.13
0.51
0.61
-1.26
0.01
-0.1
-0.01
Interest paid
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to May 31, 2026; growth uses fiscal years. Valuation uses the share price of $0.00 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-3,611.0%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-100.0%
Revenue vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-41.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-71.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-61.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
199.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
320.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
-7.6%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.00x
Current assets / current liabilities.
Quick ratio
0.00x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.00x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.00
Cash from operations / diluted weighted shares.
Book value per share
-$0.00
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
Earnings yield
-287.8%
Net income / market cap (the inverse of P/E).
What was CNBX Pharmaceuticals Inc.'s revenue in fiscal 2025?
CNBX Pharmaceuticals Inc. reported revenue of $0.0 for fiscal 2025, 100% lower than the year before.
Was CNBX Pharmaceuticals Inc. profitable in fiscal 2025?
No. It reported a net loss of $314.0K.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.